Fatty Acid Oxidation Disorders (FAODs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Fatty Acid Oxidation Disorders (FAODs) Market Outlook
Thelansis’s “Fatty Acid Oxidation
Disorders (FAODs) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2024 To 2034" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Fatty Acid
Oxidation Disorders (FAODs) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Fatty Acid
Oxidation Disorders (FAODs) Overview
Fatty Acid
Oxidation Disorders (FAODs) are a group of inherited metabolic conditions that
result in an accumulation of fatty acids and a decrease in cell energy
metabolism. Each fatty acid oxidation disorder is caused by a specific enzyme
defect in the fatty acid metabolic pathway and has an impact on dietary and
stored fat utilisation. The presentation of a FAOD varies depending on the
disorder, but common elements may be observed and ultimately require similar
treatment. Initial presentations of the FAODs in the neonatal period with
severe symptoms include cardiomyopathy, while liver dysfunction and hypoketotic
hypoglycemia are common during infancy and childhood. Fatty Acid Oxidation
Disorders (FAODs) are all inherited in an autosomal recessive manner. Patients
will have inherited two copies of a FAOD with a mutation or variant in the DNA
sequence. Each pregnancy will have a one-in-four chance of a child being
affected, a one-in-two chance of being an unaffected carrier, and a one-in-four
chance of being unaffected and not a carrier.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment